AstraZeneca ready to vaccinate half of Great Britain for coronavirus by SEPTEMBER by: Ethan Huff for Natural News
Where will the first vaccines for the Wuhan coronavirus (COVID-19) be unleashed? In Great Britain, assuming a scheme hatched by the British government to vaccinate half the population by September is a success.
Reports indicate that drug giant AstraZeneca has been contracted by the United Kingdom to turn an experimental Wuhan coronavirus (COVID-19) vaccine developed by scientists at the University of Oxford into 30 million commercial doses of the jab before the fall.
United Kingdom Business Secretary Alok Sharma recently announced that a global licensing deal worth £130 million ($160 million) has been signed between Oxford and AstraZeneca. And the aim is to vaccinated half of the entire U.K. population by the end of summer.
If this test vaccine can be “proven” to provide protection against the Wuhan coronavirus (COVID-19), the plan is to have AstraZeneca produce another 70 million doses of it for a total of 100 million doses. And Sharma wants to see this happen “as soon as possible.”
To help move things along even more quickly, Sharma has allotted another £84 million ($103 million) in taxpayer monies to supply both Oxford and Imperial College London, which is also working on the project, with the funds they require to ramp up production on their “groundbreaking potential vaccines.”
£65.5 million ($80 million) of this has been earmarked for Oxford, while Imperial will receive the remaining £18.5 million ($23 million). This is on top of £47 million ($58 million) that was handed out to other scientists who are all “racing for a cure” for the Wuhan coronavirus (COVID-19).
Listen below to The Health Ranger Report as Mike Adams, the Health Ranger, talks about how mandatory vaccination is a form of medical rape, and that the penalty should be felony assault:
Great Britain wants to deliver coronavirus vaccines to the Third World “at the lowest cost possible”
Oxford is just about finished with the first phase of its human trials, while Imperial is on track to begin its trial in June, followed by a second one in October. Before long, there will eventually be a vaccine available for everyone, though it is unclear if all Brits will be forced to receive it.
“Our scientists are at the forefront of vaccine development,” Sharma is quoted as saying. “This deal with AstraZeneca means that if the Oxford University vaccine works, people in the U.K. will get the first access to it, helping to protect thousands of lives.”
He went on to state that 100 million doses of the Oxford Wuhan coronavirus (COVID-19) vaccine will be delivered “in total, ensuring that in addition to supporting our own people, we are able to make the vaccines available to developing countries at the lowest cost possible.”
This all directly coincides with President Trump’s efforts here in the U.S. to develop a Wuhan coronavirus (COVID-19) vaccine as part of his “Operation Warp Speed” initiative.
Trump recently hired on Moncef Slaoui of Moderna, the company that has been tasked with developing a U.S. vaccine for the Wuhan coronavirus (COVID-19), to oversee the mass distribution of jabs here in America once they are ready for commercial release.
In other words, it is now a race to see which country can unveil an “effective” Wuhan coronavirus (COVID-19) vaccine the fastest, and Sharma believes that the U.K. will beat out the U.S. in reaching the finish line first.
“The U.K. continues to lead the global response to find a vaccine,” Sharma is quoted as saying, adding that the British government “is backing our scientists to do this as quickly as possible.”